Home > Remogliflozin etabonate

molecules of the month

<< Back to January

Remogliflozin etabonate

Recent Publication

SGLT1-sparing oral SGLT2 inhibitor prodrug

launched in India for diabetes, 100 mg BID

from mouse urine drug metabolite and opt.

Bioorg. Med. Chem., Jan. 22, 2021

Kissei Pharma / Toho University, JP

The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes. Interestingly, the lead for this drug…

this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.

LEARN MORE

Remogliflozin etabonate

this content is exclusive to Premium members

this content is exclusive to
Premium members